PBMs, Payers, Employers Anticipate Growing Weight Loss Medication Cost Trends

  • Jan 12, 2023

    In October, the FDA granted a fast-track designation for tirzepatide, a medication to treat obese adults or overweight adults with weight-related comorbidities. As such, the agency will likely fully approve the drug in the next few months, according to drug pricing and market access professionals who spoke with AIS Health. They say the decision will have a major impact on PBMs, payers and employers.  

    Taken together with the FDA’s June 2021 approval of Wegovy (semaglutide) for weight management, tirzepatide’s arrival on the market means “this is really the beginning of the windfall of weight loss drug utilization and costs for employers,” Chantell Sell Reagan, Pharm.D., director and national pharmacy clinical leader at WTW, tells AIS Health, a division of MMIT. 

    Read more
  • Tim Casey

    Tim has worked as a reporter and editor for more than 20 years. Before joining AIS Health in December 2021, he was a business reporter covering the commercial real estate industry’s capital markets for four years. He previously covered health care business issues for two medical publishing companies and high school, college and professional sports for the Sacramento Bee newspaper. Tim has a B.A. in Psychology from the University of Notre Dame and an M.B.A. from Georgetown University.

Related Posts

The Latest
Meet Our Reporters

Meet Our Reporters

×
×